Breaking Finance News

JPMorgan Chase & Co. downgraded Albany Molecular Research, Inc. (NASDAQ:AMRI) to Neutral in a report released today.

JPMorgan Chase & Co. has downgraded Albany Molecular Research, Inc. (NASDAQ:AMRI) to Neutral in a report released on Thursday June 08, 2017.

Just yesterday Albany Molecular Research, Inc. (NASDAQ:AMRI) traded -100.00% lower at $21.70. The company’s 50-day moving average is $21.72 and its 200-day moving average is $18.41. The last stock close price is up 18.06% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 531,221 shares of the stock were exchanged, down from an average trading volume of 1,270,940

See Chart Below

Albany Molecular Research, Inc. (NASDAQ:AMRI)

Albany Molecular Research, Inc. has a 52 week low of $13.01 and a 52 week high of $22.17 The company’s market cap is currently $0.

General Information About Albany Molecular Research, Inc. (NASDAQ:AMRI)

Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.